Zacks Investment Research cut shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) from a buy rating to a hold rating in a research report report published on Wednesday, October 18th.
According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “
A number of other brokerages also recently issued reports on RTTR. Maxim Group reissued a hold rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. Chardan Capital reduced their price objective on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a buy rating for the company in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Ritter Pharmaceuticals presently has an average rating of Buy and a consensus price target of $2.92.
Ritter Pharmaceuticals (RTTR) opened at 0.369 on Wednesday. The company’s market capitalization is $5.44 million. The stock has a 50 day moving average price of $0.44 and a 200-day moving average price of $0.44. Ritter Pharmaceuticals has a 52 week low of $0.32 and a 52 week high of $3.75.
Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). On average, equities analysts predict that Ritter Pharmaceuticals will post ($0.42) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Ritter Pharmaceuticals, Inc. (RTTR) Cut to Hold at Zacks Investment Research” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/zacks-investment-research-lowers-ritter-pharmaceuticals-inc-rttr-to-hold.html.
An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. raised its position in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 105,409 shares of the biotechnology company’s stock after acquiring an additional 76,046 shares during the quarter. KCG Holdings Inc. owned approximately 0.91% of Ritter Pharmaceuticals worth $150,000 as of its most recent SEC filing. 2.25% of the stock is currently owned by institutional investors.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.